Third COVID vaccine provides ‘significant boost’ in antibody response in patients with IBD
Immunosuppressed patients with inflammatory bowel disease who received a third COVID-19 vaccine demonstrated improved antibody binding, although the response was reduced in patients receiving infliximab and tofacitinib.In a study published in The Lancet Gastroenterology and Hepatology, researchers noted that since patients with IBD were not included in COVID-19 vaccine trials, there are limited data on vaccine efficacy in these patients. Reports have since revealed that patients taking infliximab or tofacitinib had reduced antibody responses to the vaccines — even after a second dose —Read More
